SRC and cancer: By correlating drug sensitivity with the gene expression of cancer cell lines (n = 670), we identified Dasatinib, a potent Abl/Src inhibitor, with the efficacy negatively correlated with several immune biomarkers (CD274, CD47, PDCD1LG2), that are preferentially expressed by cancer cells (Figure 6B).